These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 34451391

  • 41. Fecal microbiota composition of breast-fed infants is correlated with human milk oligosaccharides consumed.
    Wang M, Li M, Wu S, Lebrilla CB, Chapkin RS, Ivanov I, Donovan SM.
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):825-33. PubMed ID: 25651488
    [Abstract] [Full Text] [Related]

  • 42. Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea.
    Battaglioli EJ, Hale VL, Chen J, Jeraldo P, Ruiz-Mojica C, Schmidt BA, Rekdal VM, Till LM, Huq L, Smits SA, Moor WJ, Jones-Hall Y, Smyrk T, Khanna S, Pardi DS, Grover M, Patel R, Chia N, Nelson H, Sonnenburg JL, Farrugia G, Kashyap PC.
    Sci Transl Med; 2018 Oct 24; 10(464):. PubMed ID: 30355801
    [Abstract] [Full Text] [Related]

  • 43. Bovine Milk Oligosaccharides and Human Milk Oligosaccharides Modulate the Gut Microbiota Composition and Volatile Fatty Acid Concentrations in a Preclinical Neonatal Model.
    Wang M, Monaco MH, Hauser J, Yan J, Dilger RN, Donovan SM.
    Microorganisms; 2021 Apr 21; 9(5):. PubMed ID: 33919138
    [Abstract] [Full Text] [Related]

  • 44. Butyrate Differentiates Permissiveness to Clostridioides difficile Infection and Influences Growth of Diverse C. difficile Isolates.
    Pensinger DA, Fisher AT, Dobrila HA, Van Treuren W, Gardner JO, Higginbottom SK, Carter MM, Schumann B, Bertozzi CR, Anikst V, Martin C, Robilotti EV, Chow JM, Buck RH, Tompkins LS, Sonnenburg JL, Hryckowian AJ.
    Infect Immun; 2023 Feb 16; 91(2):e0057022. PubMed ID: 36692308
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Prenatal Human Milk Oligosaccharides (HMOs) in the Context of BMI, Gestational Weight Gain, and Lipid Profile-An Association Study in Pregnant Women with Overweight or Obesity.
    Schönbacher L, Treichler C, Brandl W, Köfeler HC, Fluhr H, Jantscher-Krenn E, van Poppel MNM.
    Mol Nutr Food Res; 2024 Jan 16; 68(2):e2300533. PubMed ID: 38085123
    [Abstract] [Full Text] [Related]

  • 47. Effects of addition of 2-fucosyllactose to infant formula on growth and specific pathways of utilization by Bifidobacterium in healthy term infants.
    Wallingford JC, Neve Myers P, Barber CM.
    Front Nutr; 2022 Jan 16; 9():961526. PubMed ID: 36211486
    [No Abstract] [Full Text] [Related]

  • 48. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
    Pipek B, Valentová H, Fojtík P, Urban O.
    Cas Lek Cesk; 2022 Jan 16; 161(3-4):126-130. PubMed ID: 36100450
    [Abstract] [Full Text] [Related]

  • 49. Engineering two species of yeast as cell factories for 2'-fucosyllactose.
    Hollands K, Baron CM, Gibson KJ, Kelly KJ, Krasley EA, Laffend LA, Lauchli RM, Maggio-Hall LA, Nelson MJ, Prasad JC, Ren Y, Rice BA, Rice GH, Rothman SC.
    Metab Eng; 2019 Mar 16; 52():232-242. PubMed ID: 30557615
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Clostridium scindens secretome suppresses virulence gene expression of Clostridioides difficile in a bile acid-independent manner.
    Saenz C, Fang Q, Gnanasekaran T, Trammell SAJ, Buijink JA, Pisano P, Wierer M, Moens F, Lengger B, Brejnrod A, Arumugam M.
    Microbiol Spectr; 2023 Sep 26; 11(5):e0393322. PubMed ID: 37750706
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Trehalose-Induced Remodelling of the Human Microbiota Affects Clostridioides difficile Infection Outcome in an In Vitro Colonic Model: A Pilot Study.
    Buckley AM, Moura IB, Arai N, Spittal W, Clark E, Nishida Y, Harris HC, Bentley K, Davis G, Wang D, Mitra S, Higashiyama T, Wilcox MH.
    Front Cell Infect Microbiol; 2021 Sep 26; 11():670935. PubMed ID: 34277467
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA, Riley TV.
    Lett Appl Microbiol; 2022 Sep 26; 75(3):526-536. PubMed ID: 35119124
    [Abstract] [Full Text] [Related]

  • 57. Safety and efficacy of a probiotic-containing infant formula supplemented with 2'-fucosyllactose: a double-blind randomized controlled trial.
    Alliet P, Vandenplas Y, Roggero P, Jespers SNJ, Peeters S, Stalens JP, Kortman GAM, Amico M, Berger B, Sprenger N, Cercamondi CI, Corsello G.
    Nutr J; 2022 Feb 22; 21(1):11. PubMed ID: 35193609
    [Abstract] [Full Text] [Related]

  • 58. Blends of Human Milk Oligosaccharides Confer Intestinal Epithelial Barrier Protection in Vitro.
    Natividad JM, Rytz A, Keddani S, Bergonzelli G, Garcia-Rodenas CL.
    Nutrients; 2020 Oct 05; 12(10):. PubMed ID: 33027993
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. 2'-Fucosyllactose Promotes Colonization of Akkermansia muciniphila and Prevents Colitis In Vitro and in Mice.
    Liu X, Zhang B, Zhang Y, Li W, Yin J, Shi A, Wang J, Wang S.
    J Agric Food Chem; 2024 Mar 06; 72(9):4765-4776. PubMed ID: 38393978
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.